Real-World Study Measures Lenire’s Effectiveness in Treating Tinnitus
The study found Lenire’s real-world effectiveness in treating tinnitus to be consistent with clinical trial results.
Tag: Neuromod
All
Latest
All
Latest
Case Study: Using Lenire on Patient With Acoustic Neuroma
In this case study, a clinical audiologist used Neuromod’s Lenire to treat a problem with tinnitus in a patient with acoustic neuroma.
All
Latest
Neuromod Appoints Eric Timm as US CEO
Neuromod Devices Ltd, the medical device company which specializes in neuromodulation technologies, has announced the appointment of Eric Timm as Chief Executive Officer of its recently established US entity, Neuromod USA Inc, effective from October 1, 2021.
Neuromod Appoints Rosemarie Tully as COO
In addition to her current responsibilities for corporate development and strategy, Ms Tully will now assume responsibility for all of Neuromod’s operating activities, including manufacturing, supply chain, regulatory, quality, and compliance functions. Ms Tully will continue to report to Dr Ross O’Neill, Chief Executive Officer of Neuromod.
Read More
Neuromod Appoints Florian Elsaesser as Chief Commercial Officer
Elsaesser, a hearing aid industry expert, has worked in the sector for over 12 years in various executive positions for Sivantos and Siemens Audiology.
Read More
American and British Tinnitus Associations Announce Partnership
The American Tinnitus Association (ATA) and British Tinnitus Association (BTA) have announced...
Read More
Neuromod Closes on $8.75 Million Funding Round
Proceeds from the financing will be used to accelerate ongoing European commercialization of the Company’s Lenire tinnitus treatment device; to scale-up manufacturing capacity to meet anticipated European demand, and to progress the Company’s US regulatory strategy to secure market entry into the United States, according to Neuromod’s announcement.
Read More
Neuromod Names New Members of Senior Leadership Team
Neuromod announces the appointment of Deborah Arthur as Head of Quality and Regulatory Affairs, Suzanne O’Rourke as Director of Quality and Regulatory Affairs, and Cathal Mc Fadden as Director of Operations.
Read More
Richard Tyler Appointed to Neuromod’s Clinical Advisory Board
A clinical expert in tinnitus and audiology, Tyler is a pioneer in the advancement of tinnitus research and treatment, founding the annual International Conference on Management of Tinnitus and Hyperacusis more than 26 years ago.
Read More
Neuromod Devices Announces New Appointment to Board of Directors
Neuromod Devices Limited (“Neuromod”), an Irish medical technology company specializing in non-invasive neuromodulation technologies, is pleased to announce that Christopher M. Smith is a Strategic Advisor to the Board as of June 1, 2018 and will join the company’s Board of Directors from January 3, 2019.
Read More
The International Conference on the Management of the Tinnitus and Hyperacusis Patient to Take Place June 14-15, 2018 at The University of Iowa
This conference is intended for otologists, audiologists, psychologists, hearing aid specialists, and nurses who provide clinical management services for patients with tinnitus.
Read More
Neuromod Appoints Dr Hubert Lim as Chief Scientific Officer
Lim’s work has a strong focus on the improvement of invasive and non-invasive neurostimulation approaches for treating unmet medical needs in hearing and other therapeutic areas.
Read More
Multisensory Tinnitus Treatment Receives Certification in Ireland
Neuromod Devices announced that it has secured the CE Mark—certified regulatory approval in Europe—for its mutebutton multisensory tinnitus treatment device.
Read More